Ergocalciferol

Generic Name: Ergocalciferol

Brand Names: Drisdol, Mvi Pediatric

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₄₄O

CAS Number: 50-14-6

Unique Ingredient Identifier: VS041H42XC

Background: Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931...

Indication: Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.

Hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This condition produces decreased calcium and increased phosphorus levels.
...

Associated Conditions: Deficiency, Vitamin A, Deficiency, Vitamin D, Hypoparathyroidism, Hypophosphatemia, Familial, Vitamin D Resistant Rickets

Associated Therapies: Dietary supplementation

Clinical Trials

Oral Vitamin D2 for Prevention of COVID-19

Not Applicable

Recruiting

Conditions: Healthy Volunteers

Interventions: Other: placebo
Drug: Vitamin D2

First Posted Date: 2023-01-06

Last Posted Date: 2023-01-06

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 218

Registration Number: NCT05673980

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn

Phase 2

Recruiting

Conditions: Burn Injury
Chronic Pain

Interventions: Drug: Ergocalciferol
Drug: Placebo

First Posted Date: 2022-11-16

Last Posted Date: 2024-06-13

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 40

Registration Number: NCT05619289

Locations: 🇺🇸
University Of North Carolina, Chapel Hill, North Carolina, United States

Vitamin D to ENhance TraUma REcovery

Phase 2

Completed

Conditions: Musculoskeletal Pain

Interventions: Drug: Vitamin D 2
Drug: Vitamin D2 Placebo

First Posted Date: 2022-07-14

Last Posted Date: 2024-05-07

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 71

Registration Number: NCT05458024

Locations: 🇺🇸
Cooper University Hospital, Camden, New Jersey, United States
🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 1 locations

Vitamin D Supplementation on Outcome and Disease Activity.

Not Applicable

Conditions: Rheumatoid Arthritis, Vitamin D , Disease Activity, DAS28ESR

Interventions: Drug: Placebo
Drug: Vitamin D 2

First Posted Date: 2021-06-02

Last Posted Date: 2021-06-02

Lead Sponsor: Rajavithi Hospital

Target Recruit Count: 60

Registration Number: NCT04909931

Locations: 🇹🇭
Rajavithi hospital, Bangkok, Thailand

Pregnancy Outcome and Vitamin D Level Among Vitamin D Supplementation During Pregnancy

Phase 3

Completed

Conditions: Pregnancy Outcome Among Vitamin D Supplementation During Pregnancy

Interventions: Drug: Vitamin D 2
Drug: Placebo drug

First Posted Date: 2020-10-19

Last Posted Date: 2021-09-13

Lead Sponsor: Rajavithi Hospital

Target Recruit Count: 60

Registration Number: NCT04591847

Locations: 🇹🇭
Rajavithi hospital, Bangkok, Thailand

Does Supplementing Vitamin D Deficiency Affect Fusion Healing Rates in Elective Foot and Ankle Surgery?

Early Phase 1

Completed

Conditions: Vitamin D Deficiency

Interventions: Other: Placebo
Drug: Vitamin D2

First Posted Date: 2020-06-29

Last Posted Date: 2024-06-18

Lead Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Target Recruit Count: 25

Registration Number: NCT04450199

Locations: 🇺🇸
The Foot & Ankle Institute/Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels

Early Phase 1

Completed

Conditions: Ergocalciferol

Interventions: Drug: Ergocalciferol

First Posted Date: 2018-11-20

Last Posted Date: 2020-10-29

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 44

Registration Number: NCT03747523

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Vitamin D Homeostasis in Sarcoidosis

Phase 4

Recruiting

Conditions: Sarcoidosis
Vitamin D Insufficiency

Interventions: Drug: Placebo
Drug: Calcium Citrate with Vitamin D2
Drug: Ergocalciferol

First Posted Date: 2018-08-08

Last Posted Date: 2024-12-03

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 90

Registration Number: NCT03621553

Locations: 🇺🇸
University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, United States

Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults

Phase 4

Conditions: Vitamin D2 Supplementation in Vitamin D Insufficiency

Interventions: Drug: Ergocalciferol

First Posted Date: 2017-07-25

Last Posted Date: 2017-07-26

Lead Sponsor: Chulalongkorn University

Target Recruit Count: 360

Registration Number: NCT03228862

Locations: 🇹🇭
Chulalongkorn Univerity and King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes

Phase 2

Completed

Conditions: Type 1 Diabetes

Interventions: Other: Placebo
Drug: Ergocalciferol

First Posted Date: 2017-02-08

Last Posted Date: 2024-07-10

Lead Sponsor: Benjamin U. Nwosu, MD

Target Recruit Count: 48

Registration Number: NCT03046927

Locations: 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy